Canagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Canagliflozin (Brand name: Invokana, Sulisent, Prominad), a Sodium-glucose co-transporter 2 inhibitor used to treat TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 24/April/2019, 7.37 am

Erythropoietin/Haematopoietin-derived peptide functions as a stroke medicine: Cyclic helix B peptide (CHBP), derived from Erythropoietin/Haematopoietin,  attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT, 24/April/2019, 5.56 am
April 24, 2019
Caloric restriction aids in the treatment of stroke and other neurological deficits:  Caloric restriction attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits, via up-regulation of its target genes BDNF and NAMPT, 25/April/2019, 5.58 am
April 25, 2019
Show all

Introduction: What they say

A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20+)by Prof Tzahor E, D’Uva E, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Canagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Canagliflozin (Brand name: Invokana, Sulisent, Prominad), a Sodium-glucose co-transporter 2 inhibitor used to treat TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene


From the significance of the study to Public health relevance: 

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs and (iv) a side-effect-free Natural product-based drug.

 


From research findings to Therapeutic opportunity: 

I had suggested earlier ( on 15/November/2018 at 10.02 pm and in other studies) that Canagliflozin  may protect against myocardial dysfunction (https://genomediscovery.org/2018/11/the-known-anti-hyperglycemic-agent-empagliflozin-empa-may-safeguard-your-heart-against-cardiac-dysfunction-empagliflozin-empa-a-drug-used-in-the-treatment-of-tiidm/; &

https://genomediscovery.org/2019/04/molecular-therapy-for-cardiac-dysfunction-canagliflozin-trade-name-invokana-a-medication-used-to-hyperglycemia-decreases-mir-29-expression-activates-wnt-signaling-and-its-compon/).

Evidently, a very recent study from the the Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, the George Institute for Global Health, University of New South Wales Sydney, the Royal North Shore Hospital and others shows that “Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.” This study was published, in the 14 April 2019 issue of of the prestigious journal N Engl J Med. (NEJM) (Impact factor: 79.258+) ,  by Prof. Mahaffey KW, Perkovic V, Brenner BM and others. In concordance with what I stated earlier, this study suggests that Canagliflozin lowers the risk of heart failure.  However, the mechanism of action of this drug is not known yet. 

This study suggests, for the first time,that how Canagliflozin may protect against cardiovascular diseases and aid in cardiac regeneration.  Canagliflozin, by regulating the expression of its target genes, it may: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation; and (3) cardiomyocyte (CM) redifferentiation and regeneration (fig.1).  Thus, pharmacological formulations encompassing“Canagliflozin  or its analogs, either alone or in combination with other drugs,” may be used to promote cardiac dedifferentiation and regeneration.

 

Figure1. Mechanistic insights into how canagliflozin may promote cardiac dedifferentiation and regeneration. Canagliflozin, by increasing the expression of its target genes, it may upregulate the expression of ERRB2/HER2 and promote cardiac dedifferentiation and regeneration

Figure 2. Canagliflozin may promote cardiac regeneration through induction of Her2/Erbb2

[/caption]

Given the mechanistic basis of how Canagliflozin may aid in cardiomyocyte survival and regeneration,  medical practitioners and cardiologists may consider treating myocardial patients with Canagliflozin, as it may aid in cardiomyocyte regeneration following myocardial infarction

[easy_payment currency=”USD”]


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:  Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500#

Undisclosed (mechanistic insights) information: How does  canagliflozin  increase the expression of  ERBB2/Her2?

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L.,  Canagliflozin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Canagliflozin (Brand name: Invokana, Sulisent, Prominad), a Sodium-glucose co-transporter 2 inhibitor used to treat TIIDM, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes, via up-regulation of its target gene, 24/April/2019, 7.37 am,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.